Cost Savings Program
If you are a health care professional affiliated with an employer, institution, or committee, or practicing in a state that restricts what items you may receive from manufacturers, we ask that you not accept or download any restricted items from this site. If you are a health care provider practicing in Vermont, we are required by state law to deny you permission to download any items or review any journal articles made available on this site.
Help Your Patients Save Money on BRILINTA*
Give your eligible patients the BRILINTA Savings Card for at least one month of BRILINTA free and for some patients additional savings.
- Cash-paying or commercially insured patients
Most eligible patients will receive one month free and will pay no more than $25 on each of the next 11 refills (up to $75 savings limit on each refill). Cash-paying patients will get up to $75 off (after the first $25) for each of the next 11 refills. - Medicare, Medicaid, and Massachusetts patients
Most eligible patients will receive one month free.
You can download BRILINTA Savings Cards for your eligible patients below.
*Subject to eligibility rules; restrictions apply.
You can download and print a BRILINTA Savings Card for each of your eligible patients. Every download will have a unique number that your patients will need when they call to activate their Savings Card, so please don't make duplicates of the same card.
Your patients will need to call 1-888-412-7454 to register their card, and if eligible, must present their Savings Card and a valid prescription for BRILINTA to their pharmacist.
DOWNLOAD A BRILINTA SAVINGS CARD
Savings Card Eligibility for Insured and Cash-paying Patients: This offer is good for the purchase of a 30-day supply (up to 60 tablets) of BRILINTA™ (ticagrelor) tablets and may not be used for any other product. This offer is good for the purchase of BRILINTA manufactured for AstraZeneca LP and lawfully purchased from an authorized retailer or distributor in the United States or Puerto Rico. This offer may not be combined with any other offer, including any coupon, discount, or prescription savings card program. It is not valid for mail order or prescriptions purchased under Medicaid, Medicare, TRICARE, or any other federal or state programs or if your insurance plan is paying the entire cost of the prescription. This card is not health insurance. Offer is void in Massachusetts and where prohibited by law, taxed, or restricted.
Please note that this offer is limited to 1 offer per person and is not transferable. Offer must be presented along with a valid prescription for BRILINTA at the time of purchase. If you have insurance coverage, you will receive 100% off your copay for your first prescription for BRILINTA. If you pay cash for your prescriptions, you will get your first prescription free. You will receive savings on out-of-pocket costs that exceed $25 (up to a $75 savings limit) on each refill (30-day supply of up to 60 tablets), up to 11 refills of BRILINTA. You will have up to 14 months from activation of the card to use the 1 free prescription offer plus the 11 refills of BRILINTA. Card must be activated by 06/30/2012 or offer will expire. This offer may be changed or discontinued at any time without notice.
Free Trial Eligibility: This offer is good for eligible patients for a free 30-day supply (up to 60 tablets) of BRILINTA™ (ticagrelor) tablets with a valid prescription. This offer valid only for product manufactured for AstraZeneca LP and lawfully purchased from an authorized retailer or distributor in the United States or Puerto Rico. This offer may not be used for any other product. This offer may not be combined with any other free trial, coupon, discount, prescription savings card, or other offer. This offer is void where prohibited by law, taxed, or restricted. It is illegal for any person to sell, purchase, or trade this voucher. Card must be activated by 06/30/2012 or offer will expire. You will have up to 30 days from the activation of the card to use the 1 free prescription offer. Valid for Medicare, Medicaid, or other government health care plan patients, and for Massachusetts residents. This offer may be changed or discontinued at any time without notice.
NEXT: Informational Videos
IMPORTANT SAFETY INFORMATION ABOUT BRILINTA
WARNING: BLEEDING RISK
- BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal, bleeding
- Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage
- Do not start BRILINTA in patients planned to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue BRILINTA at least 5 days prior to any surgery
- Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of BRILINTA
- If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events
WARNING: ASPIRIN DOSE AND BRILINTA EFFECTIVENESS
- Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided. After any initial dose, use with aspirin 75 mg - 100 mg per day
CONTRAINDICATIONS
- BRILINTA is contraindicated in patients with a history of intracranial hemorrhage and active pathological bleeding such as peptic ulcer or intracranial hemorrhage. BRILINTA is also contraindicated in patients with severe hepatic impairment because of a probable increase in exposure; it has not been studied in these patients. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of coagulation proteins
WARNINGS AND PRECAUTIONS
- Moderate Hepatic Impairment: Consider the risks and benefits of treatment, noting the probable increase in exposure to ticagrelor
- Premature discontinuation increases the risk of MI, stent thrombosis, and death
- Dyspnea was reported in 14% of patients treated with BRILINTA and in 8% of patients taking clopidogrel. Dyspnea resulting from BRILINTA is self-limiting. Rule out other causes
- BRILINTA is metabolized by CYP3A4/5. Avoid use with strong CYP3A inhibitors and potent CYP3A inducers. Avoid simvastatin and lovastatin doses >40 mg
- Monitor digoxin levels with initiation of, or any change in, BRILINTA therapy
ADVERSE REACTIONS
- The most commonly observed adverse reactions associated with the use of BRILINTA vs clopidogrel were Total Major Bleeding (11.6% vs 11.2%) and dyspnea (14% vs 8%)
- In clinical studies, BRILINTA has been shown to increase the occurrence of Holter-detected bradyarrhythmias. PLATO excluded patients at increased risk of bradycardic events. Consider the risks and benefits of treatment
INDICATIONS
BRILINTA is indicated to reduce the rate of thrombotic cardiovascular (CV) events in patients with acute coronary syndrome (ACS) (unstable angina, non–ST-elevation myocardial infarction, or ST-elevation myocardial infarction). BRILINTA has been shown to reduce the rate of a combined end point of CV death, myocardial infarction (MI), or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with PCI, it also reduces the rate of stent thrombosis.
BRILINTA has been studied in ACS in combination with aspirin. Maintenance doses of aspirin >100 mg decreased the effectiveness of BRILINTA. Avoid maintenance doses of aspirin >100 mg daily.
Please read full Prescribing Information, including Boxed Warnings, and Medication Guide.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
- Site Map|
- Contact Us|
- Full Prescribing Information|
- US Corporate Site|
- Privacy Statement|
- Legal Information
BRILINTA is a registered trademark and Circle T is a trademark of the AstraZeneca group of companies.
This product information is intended for US health care professionals only.
© 2012 AstraZeneca. 426606-1764500 4/12
